AXQ Capital’s Harmony Biosciences HRMY Stock Holding History

AXQ Capital’s Portfolio HRMY Stock Details HRMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-9,501	Closed	-$266K	–	1140
2026 Q1	$266K	Buy	+9,501	New	+$312K	0.03%	633
2023 Q2	–	Sell	-17,000	Closed	-$555K	–	425
2023 Q1	$555K	Buy	+17,000	New	+$774K	0.22%	151

Other funds holding HRMY

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

AXQ Capital's HRMY Position: Q2 2026 in Review

AXQ Capital sold out of Harmony Biosciences (HRMY) in Q2 2026, closing a stake of 9,501 shares — an estimated $266K sold.

AXQ Capital first reported a position in HRMY in Q1 2023 and held it in 2 quarters. The position peaked at $555K in Q1 2023. 328 funds tracked by Wall St. Rank hold HRMY as of Q2 2026.

AXQ Capital reported no remaining Harmony Biosciences position as of Q2 2026 after selling out during the quarter.
AXQ Capital sold 9,501 Harmony Biosciences shares in Q2 2026, an estimated $266K.
AXQ Capital first reported a position in Harmony Biosciences in Q1 2023 and held it in 2 quarters.
AXQ Capital's Harmony Biosciences position peaked at $555K in Q1 2023.
328 funds tracked by Wall St. Rank held Harmony Biosciences as of Q2 2026.

Based on AXQ Capital's 13F filing for Q2 2026, filed 6 Aug 2026.